与LCM同时使用的益生菌在实验性创伤后模型中增强了抗效果
Ugur Aykin1, Cumaali Demirtas2, Sezin Kiroglu Uzun2
1Department of Physiology, Hamidiye Faculty of Medicine, University of Health Sciences, Istanbul, Turkey. uguraykinmd@gmail.com.
Neurochemical research
|September 6, 2025
概括
这项研究发现,在创伤后 (PTE) 模型中,将抗药物lacosamide (LCM) 与益生菌VSL#3结合起来可以增强控制. 在创伤性脑损伤 (TBI) 的老鼠中,益生菌还改善了运动活动和疼痛值.
科学领域:
- 神经科学和药理学
- 微生物学和肠脑轴研究
背景情况:
- 创伤性脑损伤 (TBI) 可以导致创伤后 (PTE) 和相关的并发症.
- 目前对PTE的治疗可能存在限制或副作用.
- 肠道微生物在神经疾病中的作用是一个新兴的研究领域.
研究的目的:
- 为了研究与乳胺 (LCM) 结合的益生菌胰岛素,益生菌VSL#3和同生菌 (胰岛素 + VSL#3) 补充剂在治疗PTE方面的疗效.
- 评估这些干预措施对TBI后的学习,记忆,焦虑,运动性能和疼痛值的影响.
主要方法:
- 成年雄性Sprague- Dawley大鼠接受了轻微的TBI和PTE诱导.
- 在28天的时间内,动物接受了LCM,胰岛素+胰岛素,VSL#3+胰岛素或胰岛素+VSL#3+胰岛素的口腔测量.
- 使用拉辛尺度评价了活动,行为测试评估了运动,认知和与疼痛相关的功能.
主要成果:
- 单独使用LCM可以有效控制PTE相关的发作.
- 与单独使用LCM相比,LCM+VSL#3的组合显示出更好的控制.
- 使用VSL#3改善了运动活动,而VSL#3和胰岛素减轻了LCM引起的运动缺陷;共生增强了机械疼痛值.
结论:
- 益生菌VSL#3,当与抗药LCM相结合时,可以在PTE治疗中加强控制.
- 这种联合治疗可能会增强LCM的抗作用.
- 这些发现表明针对TBI和PTE的肠道微生物组具有潜在的治疗益处.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
632
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
632
Antiepileptic Drugs: Glutamate Antagonists
509
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
509
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Epilepsy and Seizures: Overview
274
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
274
Antiepileptic Drugs: Potassium Channel Activators
272
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
272
Long-term Potentiation
2.9K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.9K


